1. Seredenin, S.B., Voronina, T.A., Neznamov, G.G., et al., Pharmacogenetic concept of anxioselective effect, Vestn. Ross. Akad. Med. Nauk, 1998, no. 11, pp. 3–9.
2. Seredenin, S.B. and Voronin, M.V., Neuroreceptor mechanisms of action of afobazole, Eksp. Klin. Farmakol., 2009, vol. 72, no. 1, pp. 3–11.
3. Durnev, A.D., Zhanataev, A.K., Shreder, O.V., and Seredenin, S.B., Antimutagenic and antiteratogenic properties of afobazole, Eksp. Klin. Farmakol., 2009, vol. 72, no. 1, pp. 46–51.
4. Zenina, T.A., Gavrish, I.V., Melkumyan, D.S., et al., Neuroprotective properties of afobazole in vitro, Bull. Exp. Biol. Med., 2005, vol. 140, no. 2, pp. 194–196. https://doi.org/10.1007/s10517-005-0443-7
5. Cuevas, J., Behensky, A., Deng, W., and Katnik, C., Afobazole modulates neuronal response to ischemia and acidosis via activation of sigma-1 receptors, J. Pharmacol. Exp. Ther., 2011, vol. 339, no. 1, pp. 152–160. https://doi.org/10.1124/jpet.111.182774